Identifying cost-effective predictive rules of amyloid-β level by integrating neuropsychological tests and plasma-based markers.

Published

Journal Article

BACKGROUND: Detecting participants who are positive for amyloid-β (Aβ) pathology is germane in designing prevention trials by enriching for those cases that are more likely to be amyloid positive. Existing brain amyloid measurement techniques, such as the Pittsburgh Compound B-positron emission tomography and cerebrospinal fluid, are not reasonable first-line approaches limited by either feasibility or cost. OBJECTIVE: We aimed to identify simple and cost-effective rules that can predict brain Aβ level by integrating both neuropsychological measurements and blood-based markers. METHOD: Several decision tree models were built for extracting the predictive rules based on the Alzheimer's Disease Neuroimaging Initiative cohort. RESULTS: We successfully extracted predictive rules of Aβ level. For cognitive function variables, cases above the 45th percentile in total cognitive score (TOTALMOD), above the 52nd percentile of delayed word recall, and above the 70th percentile in orientation resulted in a group that was highly enriched for amyloid negative cases. Conversely scoring below the 15th percentile of TOTALMOD resulted in a group highly enriched for amyloid positive cases. For blood protein markers, scoring below the 57th percentile for apolipoprotein E (ApoE) levels (irrespective of genotype) enriched two fold for the risk of being amyloid positive. In the high ApoE cases, scoring above the 60th percentile for transthyretin resulted in a group that was >90% amyloid negative. A third decision tree using both cognitive and blood-marker data slightly improved the classification of cases. CONCLUSION: Our study demonstrated that the integration of the neuropsychological measurements and blood-based markers significantly improved prediction accuracy. The prediction model has led to several simple rules, which have a great potential of being naturally translated into clinical settings such as enrichment screening for AD prevention trials of anti-amyloid treatments.

Full Text

Duke Authors

Cited Authors

  • Haghighi, M; Smith, A; Morgan, D; Small, B; Huang, S

Published Date

  • January 2015

Published In

Volume / Issue

  • 43 / 4

Start / End Page

  • 1261 - 1270

PubMed ID

  • 25147105

Pubmed Central ID

  • 25147105

Electronic International Standard Serial Number (EISSN)

  • 1875-8908

International Standard Serial Number (ISSN)

  • 1387-2877

Digital Object Identifier (DOI)

  • 10.3233/jad-140705

Language

  • eng